Literature DB >> 17687358

A better prescription for drug-development financing.

Mark Kessel1, Frederick Frank.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17687358     DOI： 10.1038/nbt0807-859

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

Review 1.  Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Authors:  Uwe Marx; Tommy B Andersson; Anthony Bahinski; Mario Beilmann; Sonja Beken; Flemming R Cassee; Murat Cirit; Mardas Daneshian; Susan Fitzpatrick; Olivier Frey; Claudia Gaertner; Christoph Giese; Linda Griffith; Thomas Hartung; Minne B Heringa; Julia Hoeng; Wim H de Jong; Hajime Kojima; Jochen Kuehnl; Marcel Leist; Andreas Luch; Ilka Maschmeyer; Dmitry Sakharov; Adrienne J A M Sips; Thomas Steger-Hartmann; Danilo A Tagle; Alexander Tonevitsky; Tewes Tralau; Sergej Tsyb; Anja van de Stolpe; Rob Vandebriel; Paul Vulto; Jufeng Wang; Joachim Wiest; Marleen Rodenburg; Adrian Roth
Journal:  ALTEX       Date:  2016-05-15       Impact factor: 6.043

Review 2.  Immunoaffinity capillary electrophoresis as a powerful strategy for the quantification of low-abundance biomarkers, drugs, and metabolites in biological matrices.

Authors:  Norberto A Guzman; Timothy Blanc; Terry M Phillips
Journal:  Electrophoresis       Date:  2008-08       Impact factor: 3.535

Review 3.  Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms.

Authors:  Chris S Pridgeon; Constanze Schlott; Min Wei Wong; Minne B Heringa; Tobias Heckel; Joe Leedale; Laurence Launay; Vitalina Gryshkova; Stefan Przyborski; Rachel N Bearon; Emma L Wilkinson; Tahera Ansari; John Greenman; Delilah F G Hendriks; Sue Gibbs; James Sidaway; Rowena L Sison-Young; Paul Walker; Mike J Cross; B Kevin Park; Chris E P Goldring
Journal:  Arch Toxicol       Date:  2018-01-23       Impact factor: 5.153

Review 4.  New Zealand's drug development industry.

Authors:  Michelle Marie Lockhart; Zaheer-Ud-Din Babar; Christopher Carswell; Sanjay Garg
Journal:  Int J Environ Res Public Health       Date:  2013-09-13       Impact factor: 3.390
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.